Jane Street Group, LLC Immuno Gen, Inc. Call Options Transaction History

Jane Street Group, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 17, 2022	SELL	$4.26 - $7.48 $1.06 Million - $1.86 Million	-248,300 Reduced 73.14%	91,200 $434,000
Q4 2021 Feb 15, 2022	BUY	$4.75 - $7.5 $581,875 - $918,750	122,500 Added 56.45%	339,500 $2.52 Million
Q3 2021 Nov 16, 2021	BUY	$5.02 - $6.59 $634,026 - $832,317	126,300 Added 139.25%	217,000 $1.23 Million
Q2 2021 Aug 16, 2021	BUY	$5.79 - $8.6 $159,225 - $236,500	27,500 Added 43.51%	90,700 $598,000
Q1 2021 May 18, 2021	BUY	$6.5 - $10.53 $237,900 - $385,398	36,600 Added 137.59%	63,200 $512,000
Q4 2020 Feb 17, 2021	BUY	$3.7 - $7.66 $11,470 - $23,746	3,100 Added 13.19%	26,600 $172,000
Q3 2020 Nov 17, 2020	BUY	$3.45 - $4.89 $45,540 - $64,547	13,200 Added 128.16%	23,500 $85,000
Q2 2020 Aug 17, 2020	SELL	$3.32 - $5.34 $2,656 - $4,272	-800 Reduced 7.21%	10,300 $47,000
Q2 2018 Aug 15, 2018	SELL	$9.52 - $12.15 $258,944 - $330,480	-27,200 Reduced 71.02%	11,100 $108,000
Q3 2017 Nov 14, 2017	BUY	$5.4 - $8.47 $206,820 - $324,401	38,300	38,300 $293,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.